"CIIE Babies" powered by fast - track approval refers to the innovative drugs and medical devices in the medical and pharmaceutical field that have quickly transformed from exhibits to commodities through the China International Import Expo (CIIE) and been put into use in China, thanks to the fast - track approval mechanism.Since the first CIIE in 2018, many such products have enjoyed this advantage. For example, the INSPIRIS RESILIA aortic valve by Edwards Lifesciences made its debut in 2020 and obtained market approval in China in less than two months. Another product of the company, the SAPIEN3 transcatheter aortic valve system, completed its first commercial implantation in Shanghai within a month after its CIIE debut and was later included in the medical insurance systems of Henan and Shanghai.Novo Nordisk also benefited from this. In 2024, it launched the world's first weekly insulin formulation at the CIIE and achieved commercial launch and medical insurance approval simultaneously in China by the end of the month. This product realized a triple leap from laboratory research to exhibits and then to marketable products within just one year.These "CIIE Babies" not only reflect the rapid translation of innovative outcomes but also bring significant clinical benefits to Chinese patients, demonstrating the "China Speed" behind the "CIIE Acceleration".
|
|
|周边二手车|手机版|标签|新闻魔笔科技XinWen.MoBi - 海量语音新闻!
( 粤ICP备2024355322号-1|
粤公网安备44090202001230号 )
